MedaSorb Technologies, a Monmouth Junction, New Jersey medical device company, is planning to obtain EU’s CE Mark of certification for its flagship product CytoSorb. The company believes that its proprietary adsorbent polymer bead technology inside a hemopurifier device will offer a clinical benefit to patients in sepsis, by filtering out some of the toxins associated with septic shock.
Here’s what we know about the technology:
MedaSorb’s products are comprised of porous, adsorbent polymer beads that target molecules up to 50,000 Daltons, such as pro-inflammatory and anti- inflammatory cytokines i.e.IL-1, IL-6, TNF and Il-10, which are associated with sepsis. These cytokines are believed to be largely untouched by current blood purification techniques, including state of the art dialysis technology…
The Company’s adsorbent polymer bead technology has a porous surface, and uses size-selectivity for filtering toxins from blood and physiologic fluids. These polymer beads are slightly larger than a grain of salt and are highly compatible with blood. The beads contain pores that are large enough to allow toxins to enter the beads and adhere to the bead through hydrophobic interactions with the neutral lipophylic surface of the polymer while allowing large essential blood proteins to pass around the beads through the filter, back into the patient.